oxaliplatin

P2, N=460, Recruiting, The First Affiliated Hospital with Nanjing Medical University

P2, N=29, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital

P2, N=38, Suspended, Rutgers, The State University of New Jersey | Trial completion date: Jan 2026 --> Jan 2028 | Recruiting --> Suspended | Trial primary completion date: Jan 2026 --> Dec 2027

Observational studies have associated use of aspirin and selective cyclooxygenase inhibitors with decreased recurrence and improved survival in patients with colon cancer...This was a post hoc analysis of the phase 3 Cancer and Leukemia Group B (now Alliance)/Southwest Oncology Group 80702 randomized clinical trial (2010-2015) assessing adjuvant celecoxib vs placebo and 3 vs 6 months of adjuvant 5-fluorouracil, leucovorin, and oxaliplatin for stage III colon cancer...The findings of this post hoc analysis suggest that ctDNA status has the potential to inform clinical decision-making among patients with stage III colon cancer who should consider adjuvant celecoxib in addition to conventional chemotherapy. ClinicalTrials.gov Identifier: NCT01150045.

This research has brought to light that Alectinib targets SALL4 to modulate the FAO process, thereby reducing the oxaliplatin resistance of GC cells. These findings may open up new avenues to tackle chemoresistance in GC.

P3, N=262, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | N=192 --> 262 | Trial completion date: Jul 2027 --> Jul 2029 | Trial primary completion date: Jul 2026 --> Jul 2028

P=N/A, N=110, Active, not recruiting, Nantes University Hospital | Recruiting --> Active, not recruiting | Trial completion date: Oct 2026 --> Mar 2026 | Trial primary completion date: May 2026 --> Nov 2025

P=N/A, N=150, Not yet recruiting, Rajiv Gandhi Cancer Institute & Research Center, India

P2, N=30, Recruiting, Peking University Cancer Hospital & Institute | Not yet recruiting --> Recruiting

Importantly, CBD-induced TRPA1 activation sensitized CRC cells to oxaliplatin, triggering apoptotic-not senescent-cell death...Our findings reveal a non-canonical bioelectric-lysosomal axis that links TRPA1 activity to NRF2 destabilization in colorectal cancer. This work expands the understanding of NRF2 proteostasis under sustained oxidative stress and highlights TRPA1 as a tractable redox-modulating target for overcoming chemoresistance.

P2, N=90, Not yet recruiting, Shanghai Zhongshan Hospital

We analyzed outcomes in AGC patients with CPS 1-4 who received nivolumab in combination with capecitabine and oxaliplatin (XELOX) or fluorouracil, oxaliplatin, and leucovorin (FOLFOX) as first-line therapy between April 2021 and December 2024. This real-world retrospective study suggests modest efficacy of AGC patients with low CPS treated with nivolumab with chemotherapy. Further studies are needed to determine the optimal treatment strategy and to identify predictive biomarkers for therapy selection in patients with low-CPS AGC.